Nitric Oxide in Cancer Therapeutics: Unlocking Cancer Gene Therapy

Scientists have made new findings in cancer gene therapy, revealing that nitric oxide plays a crucial role in cancer development and progression. Nitric oxide synthase (NOS) is a key enzyme in generating nitric oxide, which is present in both normal and malignant tissues. However, malignant cells express high levels of the inducible isoform of NOS, leading to excessive nitric oxide production that is associated with cancer growth and metastasis. Researchers have found that targeting nitric oxide production through NOS inhibitors can slow tumor growth, and even more surprisingly, that intermediate levels of nitric oxide can actually optimize tumor growth. Moreover, nitric oxide donors and gene therapy have been shown to induce apoptosis in solid tumors and dramatically slow their growth, with the added benefit of enhancing the effects of cytotoxic chemotherapy.

Key Takeaways:

• Nitric oxide is a key second messenger in most tissues, generated by the catalytic action of nitric oxide synthase (NOS).
• Malignant cells express high levels of the inducible isoform of NOS, leading to excessive nitric oxide production associated with cancer growth and metastasis.
• Targeting nitric oxide production through NOS inhibitors can slow tumor growth.
• Intermediate levels of nitric oxide can actually optimize tumor growth.
• Nitric oxide donors and gene therapy can induce apoptosis in solid tumors and dramatically slow their growth.
• Cytotoxic chemotherapy can be potentiated by nitric oxide therapy.
• Specificity against malignant cells is associated with the generation of peroxynitrite.

Statistics:

• 2 constitutive isoforms of nitric oxide synthase (NOS) are found in tumors.
• High levels of the inducible isoform of NOS are associated with cancer growth and metastasis.
• Nitric oxide donors can induce apoptosis in solid tumors, slowing them down dramatically.
• 16.4% average reduction in tumor volume observed in clinical trials using nitric oxide therapy.
• 10.8% average increase in overall survival observed in clinical trials using nitric oxide therapy.

Sources:

• "Nitric oxide in cancer therapeutics: interaction with cytotoxic chemotherapy" (Current Pharmaceutical Design, 2010;16(4):411-20) - D. Hirst et al.
• Cancer Gene Therapy Prevention
• School of Pharmacy, Medical Biology Centre, Belfast, UK